Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brenetafusp - Immunocore

Next Previous
Drug Profile

Brenetafusp - Immunocore

Alternative Names: IMC-F106C; PRAME×CD3 ImmTAC therapy

Latest Information Update: 19 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunocore
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I/II Solid tumours

Most Recent Events

  • 14 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Immunocore
  • 13 Sep 2024 Adverse events and efficacy data from the phase-I PRAME-A02 trial in Ovarian cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
  • 05 Jun 2024 Phase-III clinical trials in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Inoperable/Unresectable) in Bulgaria, Czech Republic, Hungary, Denmark, Sweden, Turkey (IV) (NCT06112314) (EudraCT2023-505306-42-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top